John D Harling
Overview
Explore the profile of John D Harling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1854
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stevens R, Shrives H, Cryan J, Klimaszewska D, Stacey P, Burley G, et al.
RSC Med Chem
. 2024 Dec;
PMID: 39720740
High-throughput chemistry (HTC) and direct-to-biology (D2B) platforms allow for plate-based compound synthesis and biological evaluation of crude mixtures in cellular assays. The rise of these workflows has rapidly accelerated drug-discovery...
2.
Shah R, De Vita E, Sathyamurthi P, Conole D, Zhang X, Fellows E, et al.
J Med Chem
. 2024 Mar;
67(6):4641-4654.
PMID: 38478885
Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules that have emerged as a therapeutic modality to induce targeted protein degradation (TPD) by harnessing cellular proteolytic degradation machinery. PROTACs which ligand the E3...
3.
Stevens R, Bendito-Moll E, Battersby D, Miah A, Wellaway N, Law R, et al.
J Med Chem
. 2023 Nov;
66(22):15437-15452.
PMID: 37933562
Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules that co-opt the cell's natural proteasomal degradation mechanisms to degrade undesired proteins. A challenge associated with PROTACs is the time and resource-intensive optimization;...
4.
5.
Zhang Q, Kounde C, Mondal M, Greenfield J, Baker J, Kotelnikov S, et al.
Chem Commun (Camb)
. 2022 Sep;
58(78):10933-10936.
PMID: 36065962
Light-activable spatiotemporal control of PROTAC-induced protein degradation was achieved with novel arylazopyrazole photoswitchable PROTACs (AP-PROTACs). The use of a promiscuous kinase inhibitor in the design enables this unique photoswitchable PROTAC...
6.
Strutt R, Sheffield F, Barlow N, Flemming A, Harling J, Law R, et al.
Lab Chip
. 2022 Feb;
22(5):972-985.
PMID: 35107110
Simple diffusion of molecular entities through a phospholipid bilayer, is a phenomenon of great importance to the pharmaceutical and agricultural industries. Current model lipid systems to probe this typically only...
7.
Benowitz A, Scott-Stevens P, Harling J
Future Med Chem
. 2021 Sep;
14(3):119-121.
PMID: 34528453
No abstract available.
8.
Miah A, Smith I, Rackham M, Mares A, Thawani A, Nagilla R, et al.
J Med Chem
. 2021 Aug;
64(17):12978-13003.
PMID: 34432979
Receptor-interacting serine/threonine protein kinase 2 (RIPK2) is an important kinase of the innate immune system. Herein, we describe the optimization of a series of RIPK2 PROTACs which recruit members of...
9.
Law R, Nunes J, Chung C, Bantscheff M, Buda K, Dai H, et al.
Angew Chem Int Ed Engl
. 2021 Aug;
60(43):23327-23334.
PMID: 34416073
Focal adhesion kinase (FAK) is a key mediator of tumour progression and metastasis. To date, clinical trials of FAK inhibitors have reported disappointing efficacy for oncology indications. We report the...
10.
Activating mechanosensitive channels embedded in droplet interface bilayers using membrane asymmetry
Strutt R, Hindley J, Gregg J, Booth P, Harling J, Law R, et al.
Chem Sci
. 2021 Jun;
12(6):2138-2145.
PMID: 34163978
Droplet microcompartments linked by lipid bilayers show great promise in the construction of synthetic minimal tissues. Central to controlling the flow of information in these systems are membrane proteins, which...